Clinical Trials on Crohn's Fistula in Switzerland

Total 81 results

Pfizer
Arena is a wholly owned subsidiary of Pfizer

Recruiting

A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease (CULTIVATE)

Crohn's Disease

United States, Korea, Republic of, Netherlands, Colombia, Israel, Italy, Lebanon, Mexico, Poland, Spain, Turkey, Australia, Georgia, Czechia, Belgium, Germany, South Africa, Greece, Russian Federation, United Kingdom, Croatia, Serbia and more
Celgene

Withdrawn

A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease

Crohn Disease

United States, Spain, Belgium, Denmark, Canada, Australia, Austria, United Kingdom, Netherlands, Italy, Korea, Republic of, Germany, Portugal, Croatia, Czechia, Greece, Hungary, Israel, Poland, Russian Federation, Serbia, Slovakia, ... and more
AbbVie

Active, not recruiting

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 (U-ENDURE)

Crohn's Disease

United States, Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy and more
Hoffmann-La Roche

Completed

A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease (BERGAMOT)

Crohn Disease

United States, Israel, Spain, United Kingdom, Korea, Republic of, Canada, Australia, Austria, Czechia, France, Hungary, Italy, Netherlands, New Zealand, Russian Federation, Belgium, Brazil, Argentina, Bulgaria, Croatia, Germany, P... and more
Hoffmann-La Roche

Terminated

Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144 (JUNIPER)

Crohn Disease

United States, Israel, Spain, United Kingdom, Canada, Australia, Austria, Czechia, France, Italy, Netherlands, New Zealand, Russian Federation, Belgium, Brazil, Korea, Republic of, Germany, Bulgaria, Croatia, Hungary, Poland, Ukraine and more
Eli Lilly and Company

Completed

A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (VIVID-1)

Crohn's Disease

China, United States, Spain, Australia, Austria, Belgium, India, Japan, Korea, Republic of, Israel, Russian Federation, Canada, Hungary, Poland, Italy, Turkey, Switzerland, Germany, Brazil, Argentina, Latvia, Romania, Slovakia, Ukraine, Denmar... and more
Celgene

Active, not recruiting

Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

Crohn Disease

United States, Italy, Germany, Russian Federation, Argentina, Australia, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Chile, Croatia, Czechia, Denmark, Finland, France, Georgia, India, Ireland, Israel, Korea, Republic... and more
Janssen Research & Development, LLC

Recruiting

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD)

Crohn's Disease

United States, Denmark, Belgium, Taiwan, Italy, Korea, Republic of, Germany, United Kingdom, Israel, Malaysia, Poland, Japan, New Zealand, Netherlands, China, Canada, France, Spain, Norway, Singapore, Croatia, Brazil, Switzerland, Aus... and more
Eli Lilly and Company

Recruiting

A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (VIVID-2)

Crohn's Disease

United States, Australia, Japan, India, Korea, Republic of, Canada, Turkey, Ukraine, Brazil, Mexico, Israel, Croatia, Hungary, Latvia, Lithuania, Serbia, China, Poland, Czechia, Slovakia, Switzerland, Russian Federation, Germany, Austria and more
AbbVie

Completed

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

Crohn's Disease

United States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Ireland, Israel, Italy, Korea, Republic... and more
Galapagos NV
Gilead Sciences

Completed

Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease (DIVERSITY1)

Crohn's Disease

Hong Kong, United States, Netherlands, Belgium, France, Israel, Spain, Korea, Republic of, Taiwan, Germany, Australia, United Kingdom, Italy, India, Singapore, Portugal, Malaysia, New Zealand, Serbia, Ireland, Poland, Romania, Japan, ... and more
Galapagos NV
Gilead Sciences

Terminated

Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease (DIVERSITYLTE)

Crohn's Disease

Hong Kong, United States, Netherlands, Belgium, Israel, Spain, Korea, Republic of, Taiwan, Germany, Australia, Italy, India, Singapore, Portugal, France, Malaysia, New Zealand, Ireland, Poland, Romania, Japan, Croatia, Iceland, United... and more
AbbVie

Completed

A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies (U-EXCEL)

Crohn's Disease

United States, Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy and more
AbbVie

Completed

A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

Crohn's Disease

United States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, Germany, Greece, Hong Kong, Ireland, Israel, Italy, Japan, Korea, Republic... and more
AbbVie

Completed

A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy

Crohn's Disease

United States, Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy and more
AbbVie

Active, not recruiting

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease (FORTIFY)

Crohn's Disease

United States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hong Kong, Ireland, Israel, Italy, Japan, Korea, Republic... and more
Celgene

Recruiting

An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

Crohn Disease

United States, Argentina, Australia, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Chile, Croatia, Czechia, Denmark, Finland, France, Germany, Ireland, Israel, Italy, Korea, Republic of, Latvia, Mexico, Moldova, Republic of, ... and more
Celgene

Recruiting

A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

Crohn Disease

United States, Argentina, Australia, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Czechia, Denmark, Finland, France, Germany, Ireland, Israel, Italy, Korea, Republic of, Latvia, Mexico, Moldova, Republic of, Poland, Romani... and more
UCB Pharma

Completed

Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease (Welcome2)

Crohn's Disease

United States, France, Italy, United Kingdom, Belgium, Germany, Spain, Switzerland, Canada, Netherlands, Austria, Sweden
AbbVie

Completed

Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease

Crohn's Disease

United States, Austria, Belgium, Canada, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Netherlands, Poland, Puerto Rico, Romania, Slovakia, Spain, Switzerland, Ukraine, United Kingdom
Takeda

Completed

Entyvio (Vedolizumab) Long Term Safety Study (Entyvio PASS)

Ulcerative Colitis and Crohn's Disease

United States, Spain, Belgium, Denmark, Israel, Canada, Ireland, Croatia, France, United Kingdom, Germany, Austria, Estonia, Greece, Italy, Netherlands, Norway, Portugal, Slovenia, Sweden, Switzerland
GlaxoSmithKline

Terminated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease (SHIELD-2)

Crohn's Disease

United States, France, Netherlands, Spain, Bulgaria, Poland, Ukraine, South Africa, Sweden, Israel, Korea, Republic of, Belgium, Australia, Austria, Canada, Chile, Czechia, Denmark, Estonia, Germany, Hong Kong, Hungary, Italy, Japan, New... and more
Takeda

Recruiting

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Crohn's Disease

United States, Australia, France, Taiwan, Hungary, Korea, Republic of, Spain, Switzerland, China, Japan, Belgium, Canada, Germany, Italy, Poland, Romania, United Kingdom, Czechia, Denmark, Greece, Norway, Slovakia, Netherlands
GlaxoSmithKline

Terminated

Open-Label Extension Study of GSK1605786A (SHIELD-3)

Crohn's Disease

United States, France, Spain, Bulgaria, Poland, Ukraine, South Africa, Sweden, Israel, Korea, Republic of, Belgium, Australia, Austria, Canada, Chile, Czechia, Denmark, Estonia, Germany, Hong Kong, Hungary, Italy, Japan, New Zealand, Po... and more
UCB BIOSCIENCES, Inc.
PPD; Parexel

Completed

A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers (CRADLE)

Rheumatoid Arthritis | Crohn's Disease | Psoriatic Arthritis | Ankylosing Spondylitis | Axial Spondyloarthritis (AxSpA) | Non-radiographic Evidence-AxSpA

United States, Netherlands, Switzerland
UCB BIOSCIENCES, Inc.
PPD; Parexel

Completed

A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta (CRIB)

Rheumatoid Arthritis | Crohn's Disease | Psoriatic Arthritis | Ankylosing Spondylitis | Axial Spondyloarthritis (AxSpA) | Non-radiographic Evidence-AxSpA

Netherlands, Switzerland, United States, France
Balgrist University Hospital
University of Zurich

Terminated

3D Geplante Osteosynthesen Mit Patientenspezifischen Zielvorrichtungen

Fracture of Clavicle | Fracture of Femur | Fracture of Humerus | Fracture of Ulna Radius | Fracture of Hand | Fracture of Pelvis | Fracture of Tibia Fibula | Fracture of Skull

Switzerland
Shire

Completed

A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)

Crohn's Disease | Ulcerative Colitis

Spain, United States, Korea, Republic of, Lebanon, Australia, Russian Federation, Romania, Hungary, Portugal, Israel, Italy, Turkey, Croatia, Belgium, Bulgaria, Germany, Netherlands, Poland, New Zealand, Argentina, United Kingdom, Greec... and more
UCB Biopharma SRL

Completed

A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol) (CHERISH)

Rheumatoid Arthritis | Plaque Psoriasis | Crohn's Disease | Psoriatic Arthritis | Axial Spondyloarthritis

United States, France, Germany, Spain, Switzerland, Netherlands
Dr. Med Anas Taha
University of Basel; University of Hamburg-Eppendorf

Recruiting

Development of Machine Learning Models for the Prediction of Complications After Colonic, Colorectal and Small Intestine Anastomosis in Psychiatric and Non-psychiatric Patient Collectives (P-Study)

Postoperative Complications | Cancer | Anastomotic Leak | Diverticulitis | Psychiatric Disorder | Anastomotic Complication | Psychosomatic Disorder | Morbus Crohn | Colitis Ulcerosa | Small Intestine Anastomotic Leak

Switzerland
Centocor, Inc.
Centocor BV

Completed

A Long-term Safety Study of Infliximab (Remicade)

Arthritis, Rheumatoid | Psoriasis | Crohn Disease

United States, Canada, France, Germany, Poland, United Kingdom, Belgium, Spain, Argentina, Israel, Switzerland, Finland, Sweden, Netherlands, Austria, Hungary, Ireland, Norway, Denmark

Clinical Trials on Crohn's Fistula in Switzerland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belgium

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations